Nose-to-brain delivery represents a big challenge. In fact there is a large number of neurological diseases that require therapies in which the drug must reach the brain, avoiding the difficulties due to the blood–brain barrier (BBB) and the problems connected with systemic administration, such as drug bioavailability and side-effects. For these reasons the development of nasal formulations able to deliver the drug directly into the brain is of increasing importance. This Editorial regards the contributions present in the Special Issue “Nose-to-Brain Delivery”
Nose-to-Brain Delivery / Giunchedi, Paolo; Gavini, Elisabetta; Cristina Bonferoni, Maria. - In: PHARMACEUTICS. - ISSN 1999-4923. - 12:2(2020), p. 138. [10.3390/pharmaceutics12020138]
Nose-to-Brain Delivery
Paolo Giunchedi
;Elisabetta Gavini;
2020-01-01
Abstract
Nose-to-brain delivery represents a big challenge. In fact there is a large number of neurological diseases that require therapies in which the drug must reach the brain, avoiding the difficulties due to the blood–brain barrier (BBB) and the problems connected with systemic administration, such as drug bioavailability and side-effects. For these reasons the development of nasal formulations able to deliver the drug directly into the brain is of increasing importance. This Editorial regards the contributions present in the Special Issue “Nose-to-Brain Delivery”| File | Dimensione | Formato | |
|---|---|---|---|
|
pharmaceutics-12-00138 (1).pdf
accesso aperto
Tipologia:
Versione editoriale (versione finale pubblicata)
Licenza:
Creative commons
Dimensione
260.6 kB
Formato
Adobe PDF
|
260.6 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
